Evidence map›Paper›PMID 30763770›Full record

ArticleCellular and molecular gastroenterology and hepatology2019

MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.

Timothy A Dinh, Mark L Jewell, Matt Kanke, Adam Francisco, Ramja Sritharan, Rigney E Turnham, Seona Lee, Edward R Kastenhuber, Eliane Wauthier, Cynthia D Guy and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. cAMP signaling: a remarkably regional affair.Trends in biochemical sciences · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A framework for fibrolamellar carcinoma research and clinical trials.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Timothy A DinhCurriculum in Genetics and Molecular Biology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Mark L JewellDepartment of Medicine, School of Medicine, Duke University, Durham, North Carolina.
Matt KankeDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Adam FranciscoDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Ramja SritharanDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Rigney E TurnhamDepartment of Pharmacology, School of Medicine, University of Washington, Seattle, Washington.
Seona LeeDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Edward R KastenhuberCancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Eliane WauthierDepartment of Cell Biology and Physiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cynthia D GuyDepartment of Pathology, School of Medicine, Duke University, Durham, North Carolina.
Raymond S YeungDepartment of Surgery, University of Washington, Seattle, Washington.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Lola M ReidDepartment of Cell Biology and Physiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
John D ScottDepartment of Pharmacology, School of Medicine, University of Washington, Seattle, Washington.
Anna M DiehlDepartment of Medicine, School of Medicine, Duke University, Durham, North Carolina. Electronic address: annamae.diehl@duke.edu.
Praveen SethupathyDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York. Electronic address: pr46@cornell.edu.
Cornell University · USDuke University · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
VIRAL TRANSACTIVATIONP01CA013106 · NCI · COLD SPRING HARBOR LABORATORY · PI Camila dos Santos · 1985 to 2026
$116.8M
Hedgehog Signaling and Adult Liver RegenerationR01DK077794 · NIDDK · DUKE UNIVERSITY · PI DIEHL, ANNA MAE ELIZABETH · 2008 to 2020
$4.6M
Defective PKA Signaling in Cushing's SyndromeR01DK119192 · NIDDK · UNIVERSITY OF WASHINGTON · PI John D Scott · 2018 to 2026
$4.4M
TNF Alpha and Recovery from Alchoholic Liver InjuryR37AA010154 · NIAAA · DUKE UNIVERSITY · PI DIEHL, ANNA MAE ELIZABETH · 2009 to 2018
$3.8M
AKAP Modulation of Renal SignalingR01DK119186 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCOTT, JOHN D · 2019 to 2022
$1.5M
Local Signaling in Diabetic ComorbiditiesR01DK105542 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCOTT, JOHN D · 2015 to 2018
$1.4M
NCI NIH HHS P01 CA013106NCI NIH HHS P30 CA008748NIAAA NIH HHS R37 AA010154NIDDK NIH HHS R01 DK077794NIDDK NIH HHS R01 DK105542NIDDK NIH HHS R01 DK119186NIDDK NIH HHS R01 DK119192
6 · The paper itself

Abstract

BACKGROUND &

aimsFibrolamellar carcinoma (FLC) is a rare liver cancer that primarily affects adolescents and young adults. It is characterized by a heterozygous approximately 400-kb deletion on chromosome 19 that results in a unique fusion between DnaJ heat shock protein family member B1 (DNAJB1) and the alpha catalytic subunit of protein kinase A (PRKACA). The role of microRNAs (miRNAs) in FLC remains unclear. We identified dysregulated miRNAs in FLC and investigated whether dysregulation of 1 key miRNA contributes to FLC pathogenesis.

methodsWe analyzed small RNA sequencing (smRNA-seq) data from The Cancer Genome Atlas to identify dysregulated miRNAs in primary FLC tumors and validated the findings in 3 independent FLC cohorts. smRNA-seq also was performed on a FLC patient-derived xenograft model as well as purified cell populations of the liver to determine whether key miRNA changes were tumor cell-intrinsic. We then used clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (Cas9) technology and transposon-mediated gene transfer in mice to determine if the presence of DNAJB1-PRKACA is sufficient to suppress miR-375 expression. Finally, we established a new FLC cell line and performed colony formation and scratch wound assays to determine the functional consequences of miR-375 overexpression.

resultsWe identified miR-375 as the most dysregulated miRNA in primary FLC tumors (27-fold down-regulation; P = .009). miR-375 expression also was decreased significantly in a FLC patient-derived xenograft model compared to 4 different cell populations of the liver. Introduction of DNAJB1-PRKACA by clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 engineering and transposon-mediated somatic gene transfer in mice was sufficient to induce significant loss of miR-375 expression (P < .05). Overexpression of miR-375 in FLC cells inhibited Hippo signaling pathway proteins, including yes-associated protein 1 and connective tissue growth factor, and suppressed cell proliferation and migration (P < .05).

conclusionsWe identified miR-375 as the most down-regulated miRNA in FLC tumors and showed that overexpression of miR-375 mitigated tumor cell growth and invasive potential. These findings open a potentially new molecular therapeutic approach. Further studies are necessary to determine how DNAJB1-PRKACA suppresses miR-375 expression and whether miR-375 has additional important targets in this tumor. Transcript profiling: GEO accession numbers: GSE114974 and GSE125602.

Indexed as

AnimalsCarcinoma, HepatocellularCell ProliferationCyclic AMP-Dependent Protein Kinase Catalytic SubunitsFemaleGene Expression Regulation, NeoplasticHSP40 Heat-Shock ProteinsHumansLiverLiver NeoplasmsMice, Inbred C57BLMicroRNAsNeoplasm InvasivenessSignal TransductionXenograft Model Antitumor AssaysCyclic AMP-Dependent Protein Kinase Catalytic SubunitsDNAJB1 protein, humanHSP40 Heat-Shock ProteinsMicroRNAsMIRN375 microRNA, humanPRKACA protein, humanCancer GenomicsFibrolamellar CarcinomamiRNAPediatric Cancer

Identifiers

PMID30763770
PMCPMC6468197
OpenAlexW2913062563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.